1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Monitoring: new trials by email Literature Review of Monitoring trials Research Report on Monitoring
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA) Pembrolizumab (200mg), Pembrolizumab (400mg), Monitoring - Metastatic Urothelial Carcinoma | Phase 2 | Withdrawn | Fox Chase Cancer Center | 2023-09-01 | 2023-11-09 |
Carcinoma, Transitional Cell (1)
Benjamin Miron (1)